 "New drugs sold in India must include Indians in clinical trials: Govt")
The CDSCO (Central Drugs Standard Control Organisation) has decided to make it mandatory for pharma companies to include Indian patients in global clinical trials for drugs developed abroad, according to report in The Times of India.
The drug regulator has also decided to process medicines already approved by countries party to the ICH (International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use), such as Japan, US, on priority to reduce the time required for go-ahead to new drugs.
The ICH is a project that brings together the regulatory authorities of Europe, Japan and the US to look into scientific and technical aspects of drug registration.
The Supreme Court had constituted a 15-member committee under the Director-General of Health Services Jagdish Prasad to suggest inputs relating to clinical trials.
The clinical trial services industry in India was hit hard by reports of unethical practices a few years back. This decision could give a fillip to the industry in the near future.
One subscription. Two world-class reads.
Already subscribed? Log in
Subscribe to read the full story →*Subscribe to Business Standard digital and get complimentary access to The New York Times
Smart Quarterly
₹900
3 Months
₹300/Month
SAVE 25%
Smart Essential
₹2,700
1 Year
₹225/Month
SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months
Super Saver
₹3,900
2 Years
₹162/Month
Subscribe
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
SAVE 25%